Onco-Innovations Company Description

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments.

Its lead product candidate is ONC010, a novel inhibitor of the deoxyribonucleic acid repair enzyme polynucleotide kinase 3′-phosphatase in a nanoparticle formulation based on the drug delivery technology.

The company is headquartered in Calgary, Canada.

Onco-Innovations Limited

Country	Canada
Industry	Biotechnology
Sector	Healthcare
Employees	1
CEO	Thomas O’Shaughnessy

Contact Details

Address: 1309 - 7th Street SW Calgary, British Columbia T2R 1A5 Canada
Website	oncoinnovations.com

Stock Details

Ticker Symbol	ONCO
Exchange	Canadian Securities Exchange
Fiscal Year	May - April
Reporting Currency	CAD
ISIN Number	CA68237C1059
SIC Code	2836

Key Executives

Name	Position
Thomas O'Shaughnessy	Chief Executive Officer
Nico Mah	Chief Financial Officer and Corporate Secretary
Dr. Fadia Saad M.B.A., Ph.D.	Consultant
Dr. Frederick West	Technology Transfer Advisor